The public has mostly focused on Erbitux's ability to slow tumor growth by blocking epidermal growth factor receptor, a key growth-promoting protein that is overabundant in many cancer cells.

FORBES: Bristol, ImClone File On Erbitux

All three drugs target the epidermal growth factor receptor (EGFR), a protein that is over-expressed in cancer cells.

FORBES: Magazine Article

The mutation freezes a crucial protein called epidermal growth factor receptor in the "on" position.

FORBES: Taking Aim at Brain Cancer

Drugs like Iressa target a protein called the epidermal growth factor receptor (EGFR), which tells cells when to divide.

FORBES: Why Cancer Drugs Need Genetic Testing

Lapatinib, it turns out, also inhibits the activity of a protein called the epidermal growth factor receptor, which has been found to be important for stem-cell proliferation.

ECONOMIST: Cancer therapy

Both pills inhibit a receptor for a protein called the epidermal growth factor (EGF) that many tumors seem to depend upon to grow.

FORBES: Magazine Article